Xinhe Biotechnology
Innovative biotechnological solutions for sustainable DHA and EPA production, minimizing environmental impact and ensuring high purity
About Xinhe Biotechnology
Hubei Xinhe Biological Technology Co. operates in the biotechnology sector, focusing on the sustainable production of DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid). These are essential omega-3 fatty acids typically found in fish oil, but Xinhe Bio has developed advanced methods to extract these nutrients from alternative sources, addressing issues like limited resources, instability in output, and contamination risks associated with traditional fish oil extraction. The company serves a diverse range of clients, including those in the pharmaceutical, nutraceutical, and food industries, who require high-purity omega-3 fatty acids for their products.
Xinhe Bio operates multiple specialized centers, including R&D, quality inspection, strain reserve, strain breeding, and analysis and testing centers. These facilities are equipped with over 50 types of advanced test equipment, such as atomic absorption and high-performance liquid chromatography, ensuring rigorous quality control and innovation in their production processes.
The company's business model revolves around leveraging its proprietary technology to produce and sell high-quality DHA and EPA. Revenue is generated through direct sales to manufacturers in the health and wellness sectors, as well as through partnerships and licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Xianning, China
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 22.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2021 | $69M | $275M | CDH Investments · PICC Capital · Zhou Yahui · Shunxi Private Equity Fund Management | ↗ |
Growth signals
Latest recorded traffic for Xinhe Biotechnology is 600 monthly website visits, up 7.1% over the last three months. Xinhe Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xinhe Biotechnology in the Xianning ecosystem
The Xinhe Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
CDH Investments
PICC Capital- ZYZhou Yahui
- SMShunxi Private Equity Fund Management
- JFJiayin Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xinhe Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xinhe Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









